Elutia Inc.
ELUT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708527
No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Elutia Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 35 | 39 | +4 |
| Shares | 15.2M | 14.4M | −804.2K (−5.3%) |
| Value | $16.0M | $13.8M | −$2.16M (−13.5%) |
New holders (8)
Institutions that held Elutia Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 89,386 | $88.0K | 0.01% |
| Atom Investors LP | 44,231 | $43.3K | 0.00% |
| LRI Investments, LLC | 25,224 | $24.7K | 0.00% |
| Mercer Global Advisors Inc | 11,528 | $11.3K | 0.00% |
| Virtu Financial LLC | 10,936 | $11.0K | 0.00% |
| Marathon Capital Management | 10,000 | $9.80K | 0.00% |
| Barclays PLC | 388 | $380 | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | $1 | 0.00% |
Sold out (4)
Institutions that held Elutia Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| FNY Investment Advisers, LLC | 44,677 | $46.0K |
| Arcus Capital Partners, LLC | 30,050 | $31.6K |
| BNP Paribas Arbitrage, SA | 3 | $3 |
| Royal Bank of Canada | 242 | $0 |